Price
1,423.6
+1.07%52W Range
Market Cap
₹6,195.25 Cr
Traded: ₹14.63 Cr (0.24%) 0.0x
Free Float: ₹1,073.02 Cr (1.36% of FF traded)
Volume · 60D trend
1.03 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | -- | -- | +6.0% | -- | -- | -- |
| Return | -- | -- | -- | -1.0% | -- | -- |
| Profit | -- | +57.0% | +130.0% | -- | +26.0% | Stable |
| Sales | -- | +30.0% | +26.0% | -- | +32.0% | Stable |
Quarterly Results
Sep 2023
Jun 2023
Mar 2023
Dec 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,940 | 1,910 | 1,707 | 1,571 | 1,404 | 1,339 | 1,359 | 1,301 | 1,097 | 1,034 | 993 | 996 | 899 | 887 | 829 |
| Expenses | 1,844 | 1,824 | 1,639 | 1,509 | 1,354 | 1,290 | 1,309 | 1,258 | 1,067 | 1,005 | 964 | 968 | 873 | 867 | 810 |
| Operating Profit | 97 | 86 | 68 | 62 | 50 | 49 | 50 | 42 | 30 | 29 | 29 | 29 | 26 | 20 | 19 |
| OPM % | 5.0% | 4.5% | 4.0% | 4.0% | 3.6% | 3.6% | 3.7% | 3.3% | 2.8% | 2.8% | 2.9% | 2.9% | 2.9% | 2.0% | 2.0% |
| Other Income | 3 | 4 | -4 | 5 | 6 | 7 | 8 | 11 | 13 | 9 | 2 | 2 | 1 | 1 | 2 |
| Interest | 21 | 17 | 14 | 12 | 11 | 10 | 10 | 11 | 10 | 17 | 16 | 18 | 14 | 13 | 13 |
| Depreciation | 12 | 15 | 10 | 10 | 9 | 8 | 8 | 7 | 7 | 7 | 6 | 6 | 6 | 7 | 5 |
| Profit Before Tax | 67 | 58 | 40 | 45 | 36 | 37 | 39 | 35 | 27 | 14 | 8 | 7 | 7 | 1 | 2 |
| Tax % | 22.0% | 22.0% | 16.0% | 18.0% | 17.0% | 16.0% | 25.0% | 25.0% | 25.0% | -56.0% | 16.0% | 23.0% | 6.0% | 490.0% | -44.0% |
| Net Profit | 52 | 45 | 34 | 37 | 30 | 31 | 29 | 26 | 21 | 21 | 7 | 5 | 6 | -4 | 4 |
| Exceptional Items | -- | 0 | -8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Rs) | 8.8 | 6.4 | 6.3 | 7.3 | 6.4 | 5.9 | 5.8 | 5.4 | 4.6 | 4.8 | 4.2 | 3.2 | 15.2 | -9.1 | 8.1 |
| Sales Growth (YoY) | -- | 42.6% | 25.6% | 20.8% | 28.0% | 29.5% | 36.9% | 30.6% | 22.0% | 16.6% | 19.7% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -- | 11.9% | 8.7% | 11.9% | 4.8% | -1.5% | 4.5% | 18.6% | 6.1% | 4.1% | -0.3% | 10.8% | 1.4% | 7.0% | -- |
| OP Growth (YoY) | 94.0% | 75.5% | 36.0% | 47.6% | 66.7% | 69.0% | 72.4% | 44.8% | 15.4% | 45.0% | 52.6% | -- | -- | -- | -- |
| OP Growth (QoQ) | 12.8% | 26.5% | 9.7% | 24.0% | 2.0% | -2.0% | 19.0% | 40.0% | 3.4% | 0.0% | 0.0% | 11.5% | 30.0% | 5.3% | -- |
| Profit Growth (YoY) | -- | 9.0% | 22.9% | 33.8% | 38.5% | 22.5% | 275.2% | 360.4% | 221.8% | 663.7% | 104.8% | -- | -- | -- | -- |
| EPS Growth (YoY) | -- | 9.2% | 8.6% | 33.7% | 38.3% | 22.4% | 38.6% | 70.2% | -69.6% | 153.3% | -47.6% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 1.4% | -12.5% | 13.6% | 8.3% | 0.8% | 7.7% | 17.5% | -4.2% | 14.2% | 32.3% | -79.0% | 267.7% | -212.4% | -- |
| OP Margin | -- | 4.5% | 4.0% | 4.0% | 3.6% | 3.7% | 3.7% | 3.2% | 2.7% | 2.8% | 2.9% | 2.9% | 2.9% | 2.3% | 2.3% |
| Net Margin | -- | 2.4% | 2.0% | 2.4% | 2.1% | 2.3% | 2.1% | 2.0% | 1.9% | 2.0% | 0.7% | 0.5% | 0.7% | -0.5% | 0.5% |
| Material Cost % | -- | 89.0% | 90.0% | 90.0% | 90.0% | 90.0% | 90.0% | 91.0% | 91.0% | 91.0% | 91.0% | 91.0% | 91.0% | 92.0% | 92.0% |
| Employee Cost % | -- | 3.0% | 4.0% | 4.0% | 4.0% | 4.0% | 4.0% | 4.0% | 4.0% | 4.0% | 4.0% | 4.0% | 4.0% | 4.0% | 4.0% |
| P/S | 0.87 | 0.82 | 0.98 | 0.79 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 49.40 | 47.00 | 52.08 | 40.61 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 3.67 | 3.20 | 3.32 | 2.54 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Voting Results along with copy of Scrutinizer''s Report
Proceedings of Annual General Meeting held on Wednesday, August 19, 2026.
Transcript of Earnings Call / Conference Call
Recording of Earnings Call/ Conference Call on Unaudited Financial Results of the Company for the quarter ended June 30, 2026
Newspaper publication for Unaudited Financial Results for the quarter ended June 30, 2026
Unaudited Financial Results for the Quarter ended June 30, 2026.
Investor Presentation on Unaudited Financial Results for the Quarter ended June 30, 2026
Outcome of Board Meeting held on August 07, 2026
Business Responsibility and Sustainability Report for the Financial Year 2025-26
Annual Report for the financial year 2025-26
The 8th Annual General Meeting of the Members of Entero Healthcare Solutions Limited is scheduled to be held on Wednesday, August 19, 2026, at 12:30 p.m. (IST) through Video Conferencing/Other ....
News paper advertisement - 8th Annual General Meeting through Video conferencing / Other Audio - Visual Means (VC/OAVM) facility.
Cessation of Mr. Rajesh Shashikant Dalal as Non- Executive Independent Director of the company w.e.f. August 24, 2026.
Cessation of Mr. Rajesh Shashikant Dalal as Non- Executive Independent Director of the company w.e.f. August 24, 2026.
Certificate u/r 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended June 30, 2026
Outcome of Board Meeting held on June 26, 2026
Board has approved allotment of 1,475 (One Thousand Four Hundred and Seventy-Five) Equity Shares of Rs. 10/- (Rupees Ten) each of the Company, to the eligible employee of the Company, upon ....
Revision in tenure of re-appointment of Mr. Rajesh Shashikant Dalal (DIN: 03504969) and Ms. Sandhya Gadkari Sharma (DIN: 02005378) as Non-Executive Independent Directors of the Company.
Intimation of Closure of Trading Window
Resignation of Mr. Kevin Rohitbhai Daftary as Non- Executive Nominee Director of the company w.e.f. Jun 12, 2026.
Outcome of Board Meeting held on June 11, 2026
The grant of fresh 17,500 (Seventeen Thousand Five Hundred) Employee Stock Options under the existing 'Entero Employee Stock Option Plan 2023'.
The Board has approved the allotment of 3,420 (Three Thousand Four Hundred and Twenty) Equity Shares of Rs. 10/- (Rupees Ten) each of the Company, to the eligible employee of the Company, ....
Transcript of Earnings Call / Conference Call
Clarification on Investor Queries relating to profit attributable to owners of the Company and minority interest for the Quarter ended 31st March 2026
Annual Secretarial Compliance Report for the financial year ended March 31, 2026
Newspaper publication for Audited Financial Results of the Company for the Quarter and Year ended March 31, 2026.
Recording of Earnings Call/ Conference Call
Investor Presentation for Audited Financial Results/Statements for the Quarter and Financial Year ended March 31, 2026.
The Board has approved allotment of 7,240 (Seven Thousand Two Hundred Forty) Equity Shares of Rs. 10/- (Rupees Ten) each of the Company, to the eligible employees of the Company, upon exercise ....
The Board approved the re-appointment of Internal Auditor M/s. Ernst & Young LLP ('EY') for the next financial year 2026-27.
The grant of fresh 7,300 (Seven Thousand Three Hundred) Employee Stock Options under the existing 'Entero Employee Stock Option Plan 2023'.
the Board approved the re-appointment of Mr. Sujesh Vasudevan (DIN: 08240092), Mr. Rajesh Shashikant Dalal (DIN: 03504969) and Ms. Sandhya Gadkari Sharma (DIN: 02005378) as Non-Executive ....
Acquisition of Vishal Surgicals and Vishal Surgicals & Medicals, a Partnership Firm, through its subsidiary company Sai Pharma Distributors Private Limited through Slump Sale / Business ....
The Board has approved allotment of 7,240 (Seven Thousand Two Hundred Forty) Equity Shares of Rs. 10/- (Rupees Ten) each of the Company, to the eligible employees of the Company, upon exercise ....
Outcome of Board Meeting May 25, 2026
Outcome of Board Meeting held on May 25, 2026
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for ICICI Prudential Mutual Fund
Intimation of Earnings call on Audited Financial Results of the Company for the quarter and year ended March 31, 2026
Entero Healthcare Solutions Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2026 ,inter alia, to consider and approve and take on record ....
Confirmation order sanctioning the Scheme of Amalgamation
Certificate u/r 74(5) of SEBI(DP) Regulations, 2018 for the quarter ended March 31, 2026
Intimation of closure of trading window
Change in Senior Management Personnel
Intimation of Schedule of Analyst/Institutional Investor meet to be held on March 09, 2026
Intimation of Schedule of Analyst/Institutional Investor meet to be held on March 11, 2026.
Intimation of Schedule of Analyst/Institutional Investor meet to be held on March 06, 2026
Transcript of Earnings call
Unaudited Financial results for the quarter and nine months ended December 31, 2025 with UDIN
Recording of Earnings call/ Conference call
Credit Ratings
3Concalls
11Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Aug 2025
31 Aug 2025Jun 2025
30 Jun 2025Feb 2025
28 Feb 2025Feb 2025
28 Feb 2025Nov 2024
30 Nov 2024Aug 2024
31 Aug 2024Jun 2024
30 Jun 2024May 2024
31 May 2024Mar 2024
31 Mar 2024Held by ETFs
1 ETFs hold ENTERO · sorted by weight
Held by Mutual Funds
12 schemes hold ENTERO · sorted by weight